Tens of thousands of NHS cancer patients across England are poised to benefit from a transformative shift to their care pathway, as a faster injectable form of the world’s best-selling cancer drug becomes available on the health service. Keytruda, an immunotherapeutic agent currently deployed to fight 14 different types of cancer, has been administered via intravenous drip for close to ten years—a process that could last more than an hour in hospital. The latest injectable formulation, nonetheless, can be delivered in mere minutes, promising to substantially cut patients’ hours spent in hospital chairs and free up crucial NHS capacity. Early recipients, such as 86-year-old Shirley Xerxes from Hertfordshire, have already experienced the transformation firsthand.
A transformative change in oncology delivery
The introduction of injectable Keytruda constitutes a significant operational shift for NHS cancer centres across England. Where patients formerly needed prolonged hospital visits for intravenous infusions exceeding an hour, the new injection method condenses the entire procedure to just one or two minutes, depending on the treatment plan. This streamlining is notably valuable given that approximately 14,000 cancer patients in England commence Keytruda treatment annually, with the large proportion projected to transition to the injectable form. The operational benefits extend beyond patient convenience, allowing hospital pharmacy teams from the demanding work of preparing sterile infusion bags and allowing clinical staff to direct their time more efficiently across busy cancer centres.
NHS England’s chief clinical director for cancer, Professor Peter Johnson, has underscored the multiple advantages of this shift. The move towards a standard, rapid injection not only strengthens the patient satisfaction but also streamlines hospital workflows and resource distribution. For patients like Shirley Xerxes, the tangible effect is profound—what once consumed a substantial portion of her day now demands mere minutes, enabling her to reclaim time for personal pursuits and sustain her wellbeing between treatments. This represents the third injectable immunotherapy option now provided through the NHS, after the introduction of Opdivo in injectable format at select hospitals in the preceding year, indicating a broader shift towards patient-centred cancer care that is efficient.
- Injectable administered once every three weeks as a one-minute administration
- Optional six-weekly dosing available as two-minute injection
- Approximately 14,000 patients annually qualified for treatment
- Effective against 14 different cancer types such as lung and breast
How immunological treatment works to fight cancer
Keytruda is part of a class of drugs referred to as immunotherapy, which leverages the body’s own immune system to identify and eliminate cancer cells. Cancer cells are remarkably deceptive—they generate proteins that effectively send a “stop signal” to immune cells, preventing the body from launching an effective defence. Scientists often describe this mechanism as cancer concealed by an “invisibility cloak”, enabling malignant cells to evade detection and spread unchecked. Immunotherapy drugs like Keytruda function by inhibiting these deceptive signals, effectively removing the cloak and rendering cancer cells visible to the immune system once again.
The breakthrough in understanding this mechanism turned out to be so important that it earned two scientists—James Allison and Tasuku Honjo—the Nobel Prize for Medicine in 2018. Keytruda was one of the first immunotherapy drugs authorised for clinical use, initially for melanoma before being extended to treat numerous other cancers. Today, it stands as the globally top-selling prescription medicine, with worldwide revenue reaching £22 billion in 2025. This extraordinary commercial success underscores both the drug’s clinical effectiveness and the increasing recognition of immunotherapy as a revolutionary strategy to cancer treatment.
The research underpinning overcoming cancer’s protective barriers
When cancer cells attempt to suppress immune activity through their protective proteins, Keytruda works by stopping these inhibitory signals. This enables T-cells—the body’s frontline immune defenders—to recognise cancer cells more easily and launch an effective response. By effectively stripping away the molecular concealment mechanism, the drug restores the immune system’s natural ability to recognise and destroy malignant cells, offering patients a more focused and potentially less toxic treatment option than conventional chemotherapy methods.
Actual patient experiences with the latest injection
Shirley Xerxes, an 86-year-old from St Albans in Hertfordshire, was amongst the earliest NHS patients to experience the benefits of the injectable Keytruda at the Mount Vernon Cancer Centre near Watford. Her experience exemplifies the significant change this new formulation offers. Where she previously spent over an hour in a hospital chair receiving her treatment through intravenous infusion, the injection now takes merely minutes. “It’s made such a difference and gives me greater opportunity to enjoy life, including enjoying more gardening time,” Shirley discussed her treatment experience, highlighting how the shorter time spent in hospital leads to improved quality of life.
For numerous NHS cancer patients across England, the shift from drip-based administration to fast injection marks a major improvement in quality of life. The streamlined procedure removes the extended delays and distress caused by prolonged infusions, letting patients return to their regular activities far more quickly. With approximately 14,000 cancer patients in England starting Keytruda courses annually, the majority are anticipated to move to this quicker injectable form. This broad uptake is set not only to enhance individual patient experiences but also to liberate precious NHS facility resources and staff time, creating a win-win outcome for both patients and the medical system.
- Appointment time reduced from more than sixty minutes to only a few minutes per appointment
- Injections given every three weeks as one-minute doses or every six weeks as dual-minute treatments
- Patients enjoy significantly more time to pursue everyday pursuits and interests outside hospital
Broader implications for NHS resources and future healthcare
The introduction of injectable Keytruda marks a substantial workflow transformation for NHS cancer services. By reducing administration time from over an hour to only minutes, hospitals can significantly enhance patient throughput without expanding infrastructure or staffing levels. This operational benefit allows oncology departments to see more patients within available clinic time, ultimately decreasing wait periods across the full oncology pathway. Furthermore, the simplified preparation process—removing the requirement for pharmacy teams to prepare individual IV bags under sterile conditions—enhances operational processes and reduces the risk of preparation errors, enhancing both safety and productivity across NHS trusts.
Beyond immediate operational benefits, this development signals a broader shift towards patient-focused cancer treatment within the NHS. The time efficiencies achieved through injectable delivery could be reinvested in other aspects of patient care, such as counselling, nutritional guidance, and survivorship programmes. NHS England’s dedication to implementing this treatment across the country demonstrates the organisation’s responsiveness to clinical innovation and its determination to provide world-class cancer services. As more immunotherapy drugs become available in injectable form, the NHS is positioned to position itself as a leader in contemporary, streamlined cancer treatment delivery.
Opportunity for community-led oncology services
The swift delivery speed of injected Keytruda creates exciting possibilities for shifting cancer treatment beyond traditional hospital facilities. Community health centres and GP practices furnished with suitable resources could potentially provide these treatments, bringing treatment closer to home environments and lowering travel burdens. This transition to community delivery models could turn out to be especially valuable for elderly patients and those living in countryside locations, whilst at the same time reducing pressure on hospital oncology units and permitting them to focus resources on more challenging cases requiring specialist supervision.
- Treatment could be administered in local health centres and primary care practices with adequate facilities
- Minimised transportation needs for patients, especially those in rural or remote areas
- Hospital oncology departments freed to concentrate on complicated patients demanding specialist expertise
Market forces and patent-related factors
Keytruda’s transformation into injectable form emerges at a crucial point in the global pharmaceutical landscape. With annual sales reaching £22 billion internationally, the drug represents the globally leading prescription medicine, a position it has preserved through continuous clinical innovation and regulatory approvals across multiple cancer indications. The move towards injectable administration enhances its competitive advantage by addressing a key concern for patients—lengthy hospital visits—whilst simultaneously improving operational efficiency for health services. This advancement underscores how pharmaceutical companies are more actively meeting real-world patient needs, not simply broadening their product portfolios but substantially transforming the treatment experience.
The introduction of injectable Keytruda also affects the NHS’s long-range drug procurement strategy and budget management. As the patent environment develops and biosimilar versions of pembrolizumab are introduced in coming years, the injectable formulation may influence negotiation discussions and market competition. NHS England’s rapid uptake of this new delivery method puts the healthcare system advantageously, potentially securing priority access and negotiating power with drug makers. The simplified delivery also decreases healthcare expenses beyond the pharmaceutical cost itself, such as decreased nursing hours, reduced appointment duration, and lower facility requirements—considerations that reinforce the cost-benefit argument for widespread rollout throughout England’s cancer centres.